Wall Street analysts forecast that Jazz Pharmaceuticals (JAZZ) will report quarterly earnings of $6.62 per share in its upcoming release, pointing to a year-over-year increase of 0.3%. It is anticipated that revenues will amount to $1.18 billion, exhibiting an increase of 8.4% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 13% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have re ...

Stock of Madrigal Pharmaceuticals, Inc. (MDGL) is falling about 11 percent on Thursday morning trading despite reporting positive fourth quarter financial results, which saw a drop in net loss to $58.58 million, or $2.57 per share, from $59.42 million, or $2.71 per share, last year.The company's stock is currently trading at $436.13, down 11.33 percent or $55.71, over the previous close of $491.49 on the Nasdaq. It has traded between $265.00 and $615.00 in the past one year.The company's revenue for the qu ...

Demeetra AgBio, Inc. (hereafter "Demeetra") today announced that Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho") has renewed its research license agreement for the piggyBac® transposase technology, a widely used platform for genetic engineering in research applications.LEXINGTON, Ky., Feb. 19, 2026 /PRNewswire-PRWeb/ -- Under the renewed agreement, Taiho will continue to leverage the piggyBac technology for its internal research activities. The license has been granted directly by Demeetra, which acqui ...

Core Insights - Novartis AG (NYSE:NVS) is recognized as a leading immunotherapy stock by hedge funds, with positive results from the Phase III ALIGN study for Vanrafia (atrasentan) showing significant improvement in eGFR change compared to placebo [1] - Vanrafia received accelerated approval in the U.S. and China for reducing proteinuria in adults with IgAN, with plans for traditional approval in 2026 [2] - JPMorgan raised the price target for Novartis AG to CHF 135 from CHF 125, maintaining an Overweight rating on the shares [3] Group 1: Clinical Developments - The ALIGN study demonstrated a positive difference in eGFR change from baseline at Week 136, favoring Vanrafia across multiple timepoints and measures of kidney function [1] - Clinically meaningful results were observed at Week 132 compared to placebo, particularly in patients receiving SGLT2 inhibitors [1] - ALIGN study offers the longest follow-up period in pivotal Phase III studies for IgAN, with safety results consistent with previous findings [2] Group 2: Market Position and Analyst Ratings - Novartis AG is involved in developing a range of healthcare and pharmaceutical products, including immuno-oncology research [3] - The company is advancing its multi-asset IgAN portfolio, which includes Fabhalta and the investigational compound zigakibart [2] - JPMorgan's price target increase reflects confidence in Novartis AG's market position and growth potential [3]

Group 1 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recognized as a top immunotherapy stock by hedge funds, with RBC Capital maintaining a Hold rating and a price target of $745.00 [1] - Regeneron is expanding its immunology portfolio, with 36 abstracts related to its immunology and inflammation pipeline to be presented at the 2026 AAAAI Annual Meeting [3] - The company reported significant developments, including Phase 3 allergen-specific programs targeting ocular symptoms in adults with cat and birch allergies, and new analyses of Dupixent® across various diseases [4] Group 2 - Guggenheim raised its price target for Regeneron to $975 from $865, maintaining a Buy rating and highlighting key upcoming catalysts such as fianlimab/Libtayo LAG-3 data and an FDA decision for Eylea HD [5] - Regeneron focuses on developing therapies for diseases including cancer, eye disorders, and allergic conditions [6]

Class Action Filed Against Inovio Pharmaceuticals, Inc. (INO) - April 7, 2026 Deadline to Join - Contact The Gross Law Firm [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not require ...

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET. The event will feature presentations by Aaron Miller, MD (Corinne Dickinson Center for Multiple Sclerosis, Icahn School of Medicine, Mount Sinai) and Carlo S. Tornatore, ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsBill Sibold - CEODavid Soergel - CMOMardi Dier - CFOTina Ventura - Chief Investor Relations OfficerYasmeen Rahimi - 5-star analyst and MdConference Call ParticipantsAlex Thompson - AnalystEllie Merle - Senior Biotech Equity Research AnalystJay Olson - Md and Senior Biotechnology AnalystJonathan Wolleben - Md and Senior Research AnalystManoj Garg - AnalystMichael DiFiore - Equity Research AnalystP ...

Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses increasing from $56.3 million to $77.5 million and G&A expenses rising from $15.1 million to $19.5 million [17][18] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024, driven by increased spending on clinical programs [17][18] - The company ended Q4 2025 with $926 million in cash and equivalents, a significant increase from $469 million at the end of 2024, bolstered by proceeds from public offerings [18][19] Business Line Data and Key Metrics Changes - The ulixacaltamide program reported positive results from the Essential3 program, leading to an NDA submission for essential tremor, with a potential market of over $10 billion annually [9][10] - The relutrigine program for SCN2A and SCN8A DEEs has an initial addressable population of approximately 10,000 patients, with potential annual revenue estimated at $5 billion [12] - Vormatrigine demonstrated a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with potential annual revenue exceeding $4 billion [14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, while the broader DEE population for relutrigine is over 200,000 patients [9][12] - The company is preparing for a significant commercial launch, focusing on disease awareness and inventory management for ulixacaltamide and relutrigine [22][31] Company Strategy and Development Direction - The company aims to transform into a commercial entity, with plans to submit two NDAs and enhance its clinical portfolio in 2026 [5][6] - A comprehensive medical education campaign is planned for the upcoming American Academy of Neurology annual meeting to raise awareness about ulixacaltamide [10][25] - The company is focused on building a strong commercial organization and ensuring sufficient inventory for product launches [22][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the potential for multiple readouts from the clinical pipeline and the importance of executing pre-commercial activities [16][17] - The company is well-capitalized with a strong balance sheet, expecting to fund operations into 2028 [19] - Management emphasized the importance of understanding the competitive landscape and the unmet needs in CNS disorders [10][12] Other Important Information - The company is planning an R&D day to discuss clinical programs and a commercial day to highlight launch strategies for ulixacaltamide and relutrigine [16] - Elsunersen is being developed for a rare genetic epilepsy, with a potential NDA submission expected next year [15][16] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness for ulixacaltamide [22] Question: What additional new data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for ulixacaltamide? - The company has proposed alternative titration schedules to the FDA and is awaiting their decision [29] Question: How much capital allocation should be expected between relutrigine and ulixacaltamide? - More allocation is expected for ulixacaltamide due to its broader market potential [31] Question: What is the review timeline for the NDAs? - The company has requested priority review for relutrigine but not for ulixacaltamide, considering strategic business reasons [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present long-term efficacy data to reinforce the value of ulixacaltamide [51] Question: What are the expectations for the EMBRAVE study? - The EMBRAVE study is expected to provide valuable data, with a focus on safety and efficacy [81][84]

Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses at $77.5 million and G&A at $19.5 million [17] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024 [17] - The cash position at the end of Q4 2025 was $926 million, significantly increased from $469 million at the end of 2024, primarily due to proceeds from a follow-on public offering [18] Business Line Data and Key Metrics Changes - Ulixacaltamide showed positive results in the Essential3 program, with significant improvements in key endpoints, leading to a breakthrough designation from the FDA [8][9] - Relutrigine demonstrated strong efficacy in the EMBOLD study for SCN2A and SCN8A DEEs, with a potential annual revenue of $5 billion [12] - Vormatrigine achieved a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with expectations for multiple readouts in the next 12-18 months [13][14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, with a peak potential revenue of over $10 billion annually [9][10] - The initial addressable population for relutrigine is approximately 10,000 patients in the U.S., with a broader potential of over 200,000 patients with DEE [12] - Vormatrigine targets approximately 3 million people in the U.S. suffering from common epilepsies, with potential annual revenue exceeding $4 billion [14] Company Strategy and Development Direction - The company aims to transform into a commercial entity with two NDA submissions for ulixacaltamide and relutrigine, focusing on enhancing its clinical portfolio [6][16] - Preparations for the commercial launch of ulixacaltamide include building a commercial organization and a comprehensive medical education campaign [10][22] - The company is strategically focused on the U.S. market while acknowledging the unmet need for treatments outside the U.S. [86] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting a strong balance sheet and the potential for significant revenue opportunities across its CNS portfolio [17][19] - The company is positioned for a catalyst-rich year with multiple readouts from its innovative pipeline and plans for an R&D day to discuss clinical programs [16] - Management emphasized the importance of understanding the disease and clinical data for prescribers as part of their pre-commercial activities [24][25] Other Important Information - The company has initiated pre-launch activities for both ulixacaltamide and relutrigine, including key hires and inventory building [22][31] - The EMBRAVE3 trial for elsunersen has been updated to a single-arm, baseline-controlled study, with expectations for completion later this year [15][81] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness and prescriber education [22] Question: What additional data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for Relyxa? - The FDA did not require additional studies for alternative titration schedules, and the company is focused on ensuring the drug's tolerability [29][30] Question: How will the POWER3 study help move towards the front line setting? - The study aims to address the needs of a broader patient population with focal seizures, focusing on those who are not well managed with current treatments [40][41] Question: Why did you not request priority review for ulixacaltamide? - The decision was based on strategic considerations regarding launch timing and maximizing long-term revenue potential [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present multiple follow-up data points to reinforce the drug's value [51] Question: What is the expected utility of relutrigine across the DEE spectrum? - The company anticipates that relutrigine will serve as a foundational therapy for a diverse group of DEE patients [68][69]